FDA moves to exclude weight loss drugs from compounding chemicals list
April 30 (UPI) -- The U.S. Food and Drug Administration moved on Thursday to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular GLP-1 weight loss drugs -- from its 503B bulks list.
30 Apr 20:55 · UPI